We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App




HIV Fusion Protein Reduces Membrane Energy Barrier

By Biotechdaily staff writers
Posted on 07 Aug 2007
Researchers studying the interaction between HIV and human T-cells have found that an HIV fusion peptide lowers the energy required for the cell membrane to bend, making it easier for the virus to enter the cell.

The HIV gp120 protein initiates binding of the virus onto the host T-cell. More...
Another protein --gp41--then enables HIV to penetrate the T-cell membrane. Fusion takes place specifically through a short stretch of gp41 called fusion peptide 23 (FP-23). To better understand how FP-23 functions investigators at Carnegie Mellon University (Pittsburgh, PA, USA) used an X-ray diffusion technique to study how this HIV fusion peptide affected the energy of synthetic lipid bilayers that had been designed to mimic normal cell membranes.

Results published in the May 25, 2007, online edition of the Biophysical Journal revealed that the bending modulus of the membrane was greatly reduced upon addition of the HIV fusion peptide FP-23 to lipid bilayers. A smaller bending modulus reduced the free energy barriers required to achieve and pass through the highly curved intermediate states and thereby facilitated fusion and HIV infection. Overall, FP-23 reduced the energy required to penetrate an artificial cell membrane by up to 13-fold, depending on the thickness of that membrane.

"We found that HIV fusion peptide dramatically decreases the amount of energy needed to bend a cell-like membrane,” said first author Dr. Stephanie Tristram-Nagle, associate research professor of biological physics at Carnegie Mellon University. "This helps membranes to curve, a necessary step for HIV to fuse with an immune cell as it infects it. Reducing this energy should help explain in part how HIV infection occurs so readily. Our findings definitely will change how theoreticians think about virus-cell interactions. This same phenomenon could provide a general way that viruses use to infect cells, so it will be exciting to look at other viral systems with our experimental method.”


Related Links:
Carnegie Mellon University

Platinum Member
Xylazine Immunoassay Test
Xylazine ELISA
Verification Panels for Assay Development & QC
Seroconversion Panels
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Automatic Western Blot Analyzer
Tenfly Phoenix Blot Analyzer
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.